(Image: Getty/Victor_Tongdee)

Ketamine: The future treatment of severe mental illness?

By Maggie Lynch

In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...

Genzyme targets BBB

Genzyme targets BBB

By Nick Taylor

Genzyme is evaluating to-BBB’s G-Technology as part of a research collaboration aimed at developing treatments capable of crossing the blood-brain barrier (BBB).


Follow us


View more


Featured Suppliers

All suppliers